Procter & Gamble
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Procter & Gamble
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.
On a “strong first half of the base,” P&G increased FY2021 guidance for organic sales growth and core earnings per share despite a “sequential deceleration” in US consumption in its categories in December and so far in January.
Moeller, CFO since 2009, will retain vice chairman and COO posts and continue heading P&G’s enterprise markets, the firm’s smaller markets,
- OTC, Consumer